Soleno tumbles after Scorpion Capital takes a short position

Shares of drugmaker Soleno Therapeutics SLNO.O fall 13.4% to $67 premarket

Scorpion Capital says it has taken a short position on Soleno

Scorpion Capital's report alleges that patients on Soleno's rare genetic disorder drug, Vykat XR, experienced a rise in post-marketing adverse events, including hospitalizations and heart failure, soon after taking the medicine

In March, the US FDA approved Vykat XR to treat a rare genetic disorder called Prader-Willi syndrome

SLNO did not immediately respond to a Reuters request for comment

Stock up 72% YTD